1
|
Rabrenović V, Poskurica M, Kovačević Z,
Nešić V, Savin M, Mitić B, Dimković N, Čučković Č, Vujić D, Plješa
S, et al: Treatment of lupus nephritis by mycophenolate mofetil.
Kidney Blood Press Res. 33:297–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng
C, Liu Z and Li L: Induction therapies for class IV lupus nephritis
with non-inflammatory necrotizing vasculopathy: Mycophenolate
mofetil or intravenous cyclophosphamide. Lupus. 16:707–712. 2007.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Mok CC, Ying KY, Yim CW, Siu YP, Tong KH,
To CH and Ng WL: Tacrolimus versus mycophenolate mofetil for
induction therapy of lupus nephritis: A randomised controlled trial
and long-term follow-up. Ann Rheum Dis. 75:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Petersson L, Dexlin-Mellby L, Bengtsson
AA, Sturfelt G, Borrebaeck CA and Wingren C: Multiplexing of
miniaturized planar antibody arrays for serum protein profiling-a
biomarker discovery in SLE nephritis. Lab Chip. 14:1931–1942. 2014.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Anders HJ, Banas B and Schlöndorff D:
Signaling danger: Toll-like receptors and their potential roles in
kidney disease. J Am Soc Nephrol. 15:854–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ding Y, Liao W, He X, Xiang W and Lu Q:
CSTMP exerts anti-inflammatory effects on LPS-induced human renal
proximal tubular epithelial cells by inhibiting TLR4-mediated NF-κB
pathways. Inflammation. 39:849–859. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yang Z, Ding J, Yang C, Gao Y, Li X, Chen
X, Peng Y, Fang J and Xiao S: Immunomodulatory and
anti-inflammatory properties of artesunate in experimental colitis.
Curr Med Chem. 19:4541–4551. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Luo Q, Lin J, Zhang L, Li H and Pan L: The
anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin
concurrent exposure-induced airway inflammation and might reverse
glucocorticoid insensitivity. Int Immunopharmacol. 29:235–245.
2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lee IS, Ryu DK, Lim J, Cho S, Kang BY and
Choi HJ: Artesunate activates Nrf2 pathway-driven anti-inflammatory
potential through ERK signaling in microglial BV2 cells. Neurosci
Lett. 509:17–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bethell D, Se Y, Lon C, Tyner S, Saunders
D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P,
Schaecher K, et al: Artesunate dose escalation for the treatment of
uncomplicated malaria in a region of reported artemisinin
resistance: A randomized clinical trial. PLoS One. 6:e192832011.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Saito T, Iwano M, Matsumoto K, Mitarai T,
Yokoyama H, Yorioka N, Nishi S, Yoshimura A, Sato H, Ogahara S, et
al: Significance of combined cyclosporine-prednisolone therapy and
cyclosporine blood concentration monitoring for idiopathic
membranous nephropathy with steroid-resistant nephrotic syndrome: A
randomized controlled multicenter trial. Clin Exp Nephrol.
18:784–794. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kopp JB, Winkler CA, Zhao X, Radeva MK,
Gassman JJ, D'Agati VD, Nast CC, Wei C, Reiser J, Guay-Woodford LM,
et al: Clinical features and histology of apolipoprotein
L1-associated nephropathy in the FSGS clinical trial. J Am Soc
Nephrol. 26:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z,
Chen J, Lin H, Liu F, He Y, et al: Multitarget therapy for
induction treatment of lupus nephritis: A randomized trial. Ann
Intern Med. 162:18–26. 2015. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Zhang L, Han C, Sun C, Meng H, Ye F, Na S,
Chen F, Zhang D and Jin X: Serum levels of alpha-smooth muscle
actin and c-Met as biomarkers of the degree of severity of
Henoch-Schonlein purpura nephritis. Transl Res. 161:26–36. 2013.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Kawasaki Y, Suzuki J, Sakai N, Tanji M and
Suzuki H: Predicting the prognosis of renal dysfunction by renal
expression of alpha-smooth muscle actin in children with MPGN type
1. Am J Kidney Dis. 42:1131–1138. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Liu CY: Wakayama Symposium:
Notch-FoxL2-α-SMA axis in eyelid levator muscle development and
congenital blepharophimosis. Ocul Surf. 10:221–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Xu Y, Liu W, Fang B, Gao S and Yan J:
Artesunate ameliorates hepatic fibrosis induced by bovine serum
albumin in rats through regulating matrix metalloproteinases. Eur J
Pharmacol. 744:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Qiu S, Sun G, Zhang Y, Li X and Wang R:
Involvement of the NF-κB signaling pathway in the renoprotective
effects of isorhamnetin in a type 2 diabetic rat model. Biomed Rep.
4:628–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Hong F, Wu N, Ge Y, Zhou Y, Shen T, Qiang
Q, Zhang Q, Chen M, Wang Y, Wang L and Hong J: Nanosized titanium
dioxide resulted in the activation of TGF-β/Smads/p38MAPK pathway
in renal inflammation and fibration of mice. J Biomed Mater Res A.
104:1452–1461. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Susianti H, Iriane VM, Dharmanata S,
Handono K, Widijanti A, Gunawan A and Kalim H: Analysis of urinary
TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis.
Pathophysiology. 22:65–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang W, Wang J, Shi L, Yu L, Qian Y, Liu
Y, Wang W and Cheng S: Podocyte injury and overexpression of
vascular endothelial growth factor and transforming growth
factor-beta 1 in adriamycin-induced nephropathy in rats. Cytokine.
59:370–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Capuano A, Costanzi S, Peluso G, Zannoni
G, Vellone VG, Gremese E, Zoli A, Scott C, Beltrami CA, Romano G
and Ferraccioli G: Hepatocyte growth factor and transforming growth
factor beta1 ratio at baseline can predict early response to
cyclophosphamide in systemic lupus erythematosus nephritis.
Arthritis Rheum. 54:3633–3639. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Jiang L, Zhang Y, Sun Y, Hu L and Gao D:
Artesunate attenuates lung injury in paraquat-intoxicated rats via
downregulation of inflammatory cytokines. Clin Lab. 61:1601–1607.
2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chassin C, Goujon JM, Darche S, du Merle
L, Bens M, Cluzeaud F, Werts C, Ogier-Denis E, Le Bouguénec C,
Buzoni-Gatel D and Vandewalle A: Renal collecting duct epithelial
cells react to pyelonephritis-associated Escherichia coli by
activating distinct TLR4-dependent and -independent inflammatory
pathways. J Immunol. 177:4773–4784. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Ding Y, Yang H, Xiang W, He X, Liao W and
Yi Z: CD200R1 agonist attenuates LPS-induced inflammatory response
in human renal proximal tubular epithelial cells by regulating
TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys
Res Commun. 460:287–294. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Correa-Costa M, Braga TT, Semedo P,
Hayashida CY, Bechara LR, Elias RM, Barreto CR, Silva-Cunha C,
Hyane MI, Gonçalves GM, et al: Pivotal role of Toll-like receptors
2 and 4, its adaptor molecule MyD88, and inflammasome complex in
experimental tubule-interstitial nephritis. PLoS One. 6:e290042011.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang D, Shi J, Lv S, Xu W, Li J, Ge W,
Xiao C, Geng D and Liu Y: Artesunate attenuates
lipopolysaccharide-stimulated proinflammatory responses by
suppressing TLR4, MyD88 expression, and NF-κB activation in
microglial cells. Inflammation. 38:1925–1932. 2015. View Article : Google Scholar : PubMed/NCBI
|